Rocket


Overview
Financials
News + Filings
Key Docs
Ownership


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

IMMUTEP Ltd (PBMD) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/01/2023 6-K Quarterly results
07/31/2023 6-K Quarterly results
07/28/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"First Patient Dosed in Chemotherapy-Free Triple Combination Phase II Trial Targeting Soft Tissue Sarcoma"
05/26/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Immutep Announces Publication of Abstracts for ASCO 2023 Annual Meeting"
05/25/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Immutep Doses First Patient in AIPAC-003 Phase II/III Trial for Metastatic Breast Cancer"
05/17/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Immutep's Efti in Combination with Pembrolizumab Achieves Excellent Initial Overall Survival Benefit in 1st Line Non-Small Cell Lung Cancer"
05/16/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Immutep Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alpha in Non-Small Cell Lung Cancer"
05/08/2023 EFFECT Form EFFECT - Notice of Effectiveness:
04/28/2023 6-K Quarterly results
04/28/2023 F-3 Form F-3 - Registration statement by foreign private issuers:
03/14/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Immutep Announces Initiation of Phase II/III Trial for Eftilagimod Alpha plus Paclitaxel in Metastatic Breast Cancer"
02/09/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/06/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Immutep Reaches Enrolment Target for INSIGHT-003 Trial in 1st Line NSCLC"
01/04/2023 6-K Quarterly results
01/04/2023 6-K Quarterly results
12/08/2022 6-K Quarterly results
12/06/2022 6-K Quarterly results
11/29/2022 6-K Quarterly results
11/14/2022 6-K Quarterly results
11/14/2022 6-K Quarterly results
11/14/2022 6-K Quarterly results
11/14/2022 6-K Quarterly results
11/09/2022 6-K Quarterly results
11/04/2022 6-K Quarterly results
11/03/2022 6-K Quarterly results
10/31/2022 20-F Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
10/27/2022 6-K Quarterly results
10/25/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Quarterly Activities & Appendix 4C Cash Flow Report"
10/06/2022 6-K Quarterly results
10/05/2022 6-K Quarterly results
09/23/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Immutep Receives A$2.7 million R&D Tax Incentive from French Government"
09/01/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"APPENDIX 4E PRELIMINARY FINAL REPORT"
08/01/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Immutep Reports New Positive Interim Data from its Phase II Study of LAG-3 Candidate, Eftilagimod Alpha, in 2nd line PD-X refractory NSCLC"
07/28/2022 6-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy